Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Sirius Therapeutics Files Hong Kong IPO Application with siRNA Pipeline Targeting Coagulation and Cardiometabolic Diseases

Fineline Cube Apr 1, 2026
Company Deals

Gilead and Galapagos Forge $2.175 Billion T-Cell Engager Collaboration for Autoimmune Diseases Following Ouro Medicines Acquisition

Fineline Cube Apr 1, 2026
Company Deals

Merck & Co. Partners with Infinimmune for $838 Million Antibody Discovery Collaboration Using Human-First Platform

Fineline Cube Apr 1, 2026
Company Deals

Otsuka Pharmaceutical to Acquire Transcend Therapeutics for Up to $1.225 Billion to Expand Neuropsychiatric Pipeline

Fineline Cube Apr 1, 2026
Company Deals Digital

Abbott Integrates Precision Oncology Portfolio into Flatiron’s OncoEMR Platform to Streamline Cancer Care

Fineline Cube Mar 31, 2026
Policy / Regulatory

NMPA Finalizes Conditional Drug Approval Framework to Accelerate Access to Critical Medicines

Fineline Cube Mar 31, 2026
Company Drug

Fosun Pharma Secures NMPA Clearance for Two Novel Therapeutics: PD-1/IL-2 Fusion FXB0871 and Recombinant Hyaluronidase HLXTE-HAase02

Fineline Cube Apr 1, 2026
Company Drug

Rui Therapeutics Secures NMPA Approval for KN5501 CAR-NK Therapy in Autoimmune Diseases

Fineline Cube Apr 1, 2026
Company Deals

Keymed Biosciences Enters Global Licensing Agreement with Platina Medicines for CM336

Fineline Cube Nov 18, 2024

Keymed Biosciences Inc., a China-based biopharmaceutical company (HKG: 2162), has announced a significant licensing agreement...

Company Drug

CanSino Biologics Initiates Phase I Clinical Trial for Freeze-Dried Hib Conjugate Vaccine

Fineline Cube Nov 18, 2024

China-based biopharmaceutical company CanSino Biologics (HKG: 6185) has announced the commencement of a Phase I...

Company Deals

Hangzhou Jiuyuan Gene Engineering Passes HKEX IPO Hearing for Orthopedic Treatments

Fineline Cube Nov 18, 2024

Hangzhou Jiuyuan Gene Engineering Co., Ltd. has announced that it has successfully passed the listing...

Company Deals

NK CellTech Partners with 3SBio to Advance NK Cell Therapy Technology

Fineline Cube Nov 18, 2024

China-based natural killer (NK) cell therapy developer NK CellTech has entered into a strategic partnership...

Company Deals

Shanghai’s Matwings Secures Over $13.8 Million in Series A Financing for AI Protein Design

Fineline Cube Nov 18, 2024

Matwings, an AI-based protein design service provider headquartered in Shanghai, has announced the successful completion...

Company Drug

EMA’s CHMP Recommends Approval for MSD’s Keytruda Combo in Mesothelioma Treatment

Fineline Cube Nov 18, 2024

Merck, Sharp & Dohme Inc., (MSD; NYSE: MRK), a leading US pharmaceutical company, has announced...

Company Drug

EMA’s CHMP Recommends Approval for BMS’s Opdivo/Yervoy Combo in mCRC

Fineline Cube Nov 18, 2024

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...

Company Deals

Boston Scientific Expands Neuromodulation Portfolio with Axonics Acquisition

Fineline Cube Nov 18, 2024

Boston Scientific Corporation (NYSE: BSX), a leading player in the medical device industry, has announced...

Company Drug

Sandoz Receives EC Approval for Biosimilar to Eylea for Retinal Diseases

Fineline Cube Nov 18, 2024

Switzerland-based pharmaceutical company Sandoz (SWX: SDZ) has announced that it has received marketing approval from...

Company Medical Device

Peijia Medical Achieves First Compassionate Use of Taurus Trio TAVR System in Hong Kong

Fineline Cube Nov 18, 2024

Peijia Medical Ltd (HKG: 9996), a leading medical device company, has announced the completion of...

Company Drug

Sanofi’s Dupixent sBLA for Chronic Spontaneous Urticaria Accepted by FDA for Review

Fineline Cube Nov 18, 2024

French pharmaceutical giant Sanofi has announced that the US Food and Drug Administration (FDA) has...

Company Drug

Novo Nordisk Launches Semaglutide for Weight Management in China

Fineline Cube Nov 18, 2024

Denmark-based healthcare giant Novo Nordisk A/S (NYSE: NVO) has announced the official market launch of...

Company Drug

Sichuan Kelun-Biotech Secures NMPA Approval for Two Antibody Drug Conjugates

Fineline Cube Nov 18, 2024

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990), a leading biopharmaceutical company based in China, has...

Company Drug

Exegenesis Bio’s Gene Therapy EXG110 Earns Orphan Drug Status for Fabry Disease

Fineline Cube Nov 18, 2024

Exegenesis Bio, a leading provider of epigenetics experimental and analytical services headquartered in Hangzhou, has...

Company Deals

Shenzhen Weiguang Biological Partners with SUAT to Boost Life Science and Health Industry

Fineline Cube Nov 18, 2024

Shenzhen Weiguang Biological Products Co., Ltd. (SHE: 002880), a prominent blood products manufacturer in China,...

Company Drug

Janssen-Cilag’s Lazcluze-Rybrevant Combo Receives Positive EMA Opinion for NSCLC Treatment

Fineline Cube Nov 18, 2024

Janssen-Cilag International NV, a subsidiary of the US pharmaceutical giant Johnson & Johnson (J&J; NYSE:...

Company Drug

Shanghai Junshi Biosciences’ Toripalimab Wins UK Approval for Nasopharyngeal and Oesophageal Cancers

Fineline Cube Nov 18, 2024

Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180), a leading biopharmaceutical company based in...

Company Deals

C-Ray Therapeutics Secures Over $100 Million in Series A+ Financing for Radiopharmaceuticals

Fineline Cube Nov 18, 2024

C-Ray Therapeutics, a specialist in radiopharmaceuticals headquartered in Chengdu, has announced the successful completion of...

Company

BioNTech Acquires Biotheus for $800 Million, Enhancing Oncology Pipeline

Fineline Cube Nov 17, 2024

BioNTech (NASDAQ: BNTX), the biotech giant recognized for its role in developing the COVID-19 vaccine,...

Company

Suzhou Ribo Life Science Receives EU Approval for Phase II Trial of RBD5044

Fineline Cube Nov 16, 2024

Suzhou Ribo Life Science Co., Ltd. and its subsidiary Ribocure Pharmaceuticals AB have announced that...

Posts pagination

1 … 244 245 246 … 645

Recent updates

  • Fosun Pharma Secures NMPA Clearance for Two Novel Therapeutics: PD-1/IL-2 Fusion FXB0871 and Recombinant Hyaluronidase HLXTE-HAase02
  • Rui Therapeutics Secures NMPA Approval for KN5501 CAR-NK Therapy in Autoimmune Diseases
  • Changchun High & New Receives NMPA Approval for GenSci161 Clinical Study in Endometriosis and Hidradenitis Suppurativa
  • Sirius Therapeutics Files Hong Kong IPO Application with siRNA Pipeline Targeting Coagulation and Cardiometabolic Diseases
  • Alphamab Oncology’s Anbenitamab Meets Primary Endpoint in Phase III HER2+ Breast Cancer Neoadjuvant Study
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Fosun Pharma Secures NMPA Clearance for Two Novel Therapeutics: PD-1/IL-2 Fusion FXB0871 and Recombinant Hyaluronidase HLXTE-HAase02

Company Drug

Rui Therapeutics Secures NMPA Approval for KN5501 CAR-NK Therapy in Autoimmune Diseases

Company Drug

Changchun High & New Receives NMPA Approval for GenSci161 Clinical Study in Endometriosis and Hidradenitis Suppurativa

Company Deals

Sirius Therapeutics Files Hong Kong IPO Application with siRNA Pipeline Targeting Coagulation and Cardiometabolic Diseases

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.